X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (16380) 16380
Newspaper Article (322) 322
Newsletter (254) 254
Book Chapter (65) 65
Transcript (46) 46
Magazine Article (20) 20
Dissertation (4) 4
Book / eBook (2) 2
Book Review (2) 2
Trade Publication Article (2) 2
Web Resource (2) 2
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (12017) 12017
angiogenesis (8743) 8743
female (6304) 6304
male (5872) 5872
oncology (5225) 5225
animals (4441) 4441
cancer (4414) 4414
middle aged (4179) 4179
bevacizumab (4120) 4120
angiogenesis inhibitors - therapeutic use (3874) 3874
aged (3848) 3848
vascular endothelial growth factor (3643) 3643
endothelial growth-factor (3140) 3140
angiogenesis inhibitors (3011) 3011
angiogenesis inhibitors - adverse effects (2967) 2967
adult (2829) 2829
treatment outcome (2724) 2724
care and treatment (2703) 2703
chemotherapy (2416) 2416
metastasis (2243) 2243
angiogenesis inhibitors - administration & dosage (2234) 2234
research (2211) 2211
ophthalmology (2166) 2166
vascular endothelial growth factor a - antagonists & inhibitors (2072) 2072
tumors (2057) 2057
mice (1979) 1979
expression (1935) 1935
analysis (1735) 1735
apoptosis (1718) 1718
aged, 80 and over (1717) 1717
therapy (1714) 1714
pharmacology & pharmacy (1631) 1631
health aspects (1606) 1606
medicine & public health (1544) 1544
clinical trials (1433) 1433
cancer therapies (1427) 1427
proteins (1405) 1405
antibodies, monoclonal, humanized (1396) 1396
antineoplastic agents - therapeutic use (1361) 1361
vegf (1327) 1327
drug therapy (1320) 1320
kinases (1236) 1236
studies (1218) 1218
antineoplastic combined chemotherapy protocols - therapeutic use (1215) 1215
intravitreal injections (1193) 1193
macular degeneration (1181) 1181
ranibizumab (1163) 1163
surgery (1150) 1150
neovascularization (1144) 1144
medicine (1133) 1133
retrospective studies (1110) 1110
gene expression (1074) 1074
neoplasms - drug therapy (1074) 1074
cell biology (1067) 1067
patients (1060) 1060
inflammation (1055) 1055
risk factors (1026) 1026
survival (1013) 1013
angiogenesis inhibitors - pharmacology (1010) 1010
medicine, research & experimental (1003) 1003
physiological aspects (971) 971
review (953) 953
development and progression (950) 950
medical research (949) 949
research article (947) 947
prognosis (927) 927
neovascularization, pathologic - drug therapy (926) 926
cells (923) 923
signal transduction (915) 915
antibodies, monoclonal - therapeutic use (903) 903
breast cancer (899) 899
follow-up studies (896) 896
disease-free survival (877) 877
rats (868) 868
cell line, tumor (865) 865
hypertension (863) 863
rodents (859) 859
antibodies, monoclonal - adverse effects (855) 855
hematology (845) 845
antineoplastic agents - adverse effects (841) 841
growth factors (838) 838
hypoxia (823) 823
vascular endothelial growth factor a - metabolism (823) 823
inhibition (809) 809
prospective studies (808) 808
multidisciplinary sciences (807) 807
growth (801) 801
stem cells (787) 787
antineoplastic agents (786) 786
antibodies, monoclonal, humanized - therapeutic use (782) 782
hematology, oncology and palliative medicine (780) 780
colorectal cancer (774) 774
medical prognosis (768) 768
dose-response relationship, drug (752) 752
endothelium (752) 752
time factors (748) 748
antimitotic agents (742) 742
biochemistry & molecular biology (742) 742
antineoplastic combined chemotherapy protocols - adverse effects (734) 734
disease models, animal (733) 733
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (16792) 16792
French (104) 104
German (90) 90
Japanese (78) 78
Spanish (35) 35
Chinese (24) 24
Russian (10) 10
Polish (9) 9
Hungarian (8) 8
Italian (7) 7
Czech (5) 5
Danish (4) 4
Dutch (4) 4
Portuguese (3) 3
Swedish (3) 3
Finnish (1) 1
Hebrew (1) 1
Korean (1) 1
Norwegian (1) 1
Romanian (1) 1
Slovak (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cochrane Database of Systematic Reviews, ISSN 1469-493X, 10/2018, Volume 2018, Issue 10, p. CD007419
Background Diabetic macular oedema (DMO) is a common complication of diabetic retinopathy. Antiangiogenic therapy with anti‐vascular endothelial growth factor... 
Endocrine & metabolic | Receptors, Vascular Endothelial Growth Factor | Vascular Endothelial Growth Factor A | Macular oedema | Laser Coagulation | Visual Acuity | Retinal disease | Angiogenesis Inhibitors | Recombinant Fusion Proteins | Bevacizumab | Randomized Controlled Trials as Topic | Diabetic eye disease | Aptamers, Nucleotide | Ranibizumab | Quality of Life | Macular Edema | Diabetes | Eyes & vision | Network Meta‐Analysis | Triamcinolone | Medicine General & Introductory Medical Sciences | Diabetic Retinopathy | Retinal disease (including age‐related macular degeneration) | CLINICAL-TRIAL | RANIBIZUMAB PLUS PROMPT | RANDOMIZED CONTROLLED-TRIAL | Receptors, Vascular Endothelial Growth Factor [therapeutic use] | DEFERRED LASER | MEDICINE, GENERAL & INTERNAL | PEGAPTANIB SODIUM | Bevacizumab [adverse effects; therapeutic use] | Laser Coagulation [methods] | Aptamers, Nucleotide [adverse effects; therapeutic use] | Network Meta-Analysis | QUALITY-OF-LIFE | Macular Edema [drug therapy; etiology; surgery] | Vascular Endothelial Growth Factor A [antagonists & inhibitors] | Visual Acuity [drug effects; physiology] | COST-EFFECTIVENESS | Angiogenesis Inhibitors [adverse effects; therapeutic use] | LASER PHOTOCOAGULATION | Ranibizumab [adverse effects; therapeutic use] | Recombinant Fusion Proteins [adverse effects; therapeutic use] | INTRAVITREAL BEVACIZUMAB | Diabetic Retinopathy [complications] | Triamcinolone [adverse effects; therapeutic use] | VEGF TRAP-EYE | Bevacizumab - therapeutic use | Receptors, Vascular Endothelial Growth Factor - therapeutic use | Recombinant Fusion Proteins - adverse effects | Bevacizumab - adverse effects | Humans | Recombinant Fusion Proteins - therapeutic use | Ranibizumab - therapeutic use | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Diabetic Retinopathy - complications | Macular Edema - etiology | Ranibizumab - adverse effects | Visual Acuity - drug effects | Triamcinolone - adverse effects | Laser Coagulation - methods | Angiogenesis Inhibitors - therapeutic use | Angiogenesis Inhibitors - adverse effects | Triamcinolone - therapeutic use | Visual Acuity - physiology | Aptamers, Nucleotide - therapeutic use | Aptamers, Nucleotide - adverse effects | Macular Edema - surgery | Macular Edema - drug therapy
Journal Article
Nature reviews. Clinical oncology, ISSN 1759-4782, 2009, Volume 6, Issue 8, pp. 465 - 477
.... Although most adverse effects of VEGF inhibitors are modest and manageable, some are associated with serious and life-threatening consequences, particularly in high-risk patients and in certain clinical settings... 
ONCOLOGY | POSTERIOR LEUKOENCEPHALOPATHY SYNDROME | TYROSINE KINASE INHIBITOR | PHASE-II | OVARIAN-CANCER | PACLITAXEL PLUS BEVACIZUMAB | THROMBOTIC MICROANGIOPATHY | METASTATIC COLORECTAL-CANCER | RENAL-CELL CARCINOMA | ENDOTHELIAL GROWTH-FACTOR | COOPERATIVE-ONCOLOGY-GROUP | Humans | Antibodies, Monoclonal - therapeutic use | Neoplasm Proteins - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Benzenesulfonates - adverse effects | Bevacizumab | Brain Diseases - chemically induced | Benzenesulfonates - pharmacology | Pyridines - adverse effects | Drug Interactions | Kidney Diseases - chemically induced | Pyrroles - adverse effects | Angiogenesis Inhibitors - adverse effects | Antibodies, Monoclonal - pharmacology | Risk Factors | Angiogenesis Inhibitors - pharmacology | Forecasting | Indoles - adverse effects | Indoles - therapeutic use | Cardiovascular Diseases - chemically induced | Hemorrhage - chemically induced | Vascular Endothelial Growth Factor A - physiology | Niacinamide - analogs & derivatives | Receptors, Vascular Endothelial Growth Factor - physiology | Clinical Trials as Topic - statistics & numerical data | Neoplasm Proteins - physiology | Antibodies, Monoclonal - adverse effects | Cardiovascular Diseases - therapy | Benzenesulfonates - therapeutic use | Phenylurea Compounds | Drug Delivery Systems | Antibodies, Monoclonal, Humanized | Antineoplastic Agents - adverse effects | Angiogenesis Inhibitors - therapeutic use | Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors | Indoles - pharmacology | Antineoplastic Agents - pharmacology | Pyrroles - therapeutic use | Wound Healing - drug effects | Pyridines - therapeutic use | Hemorrhage - therapy | Pyrroles - pharmacology | Protein Kinase Inhibitors - therapeutic use | Capillary Leak Syndrome - chemically induced | Kidney Diseases - therapy | Protein Kinase Inhibitors - pharmacology | Pyridines - pharmacology | Gastrointestinal Diseases - chemically induced | Antimitotic agents | Complications and side effects | Care and treatment | Colorectal cancer | Physiological aspects | Development and progression | Poisoning | Antineoplastic agents | Vascular endothelial growth factor | Risk factors | Tumors | Cancer | Index Medicus
Journal Article
International journal of molecular sciences, ISSN 1422-0067, 2017, Volume 18, Issue 7, p. 1414
.... Mechanisms of anticancer effects of HDAC inhibitors are not uniform; they may be different and depend on the cancer type, HDAC inhibitors, doses, etc... 
Histone deacetylase inhibitors | Anti-angiogenic effect | Cell cycle arrest | Drug combinations | Histone deacetylases | Autophagy | Apoptosis | Cancer | HDAC INHIBITORS | autophagy | SUBEROYLANILIDE HYDROXAMIC ACID | HUMAN LEUKEMIA-CELLS | NITRIC-OXIDE SYNTHASE | BIOCHEMISTRY & MOLECULAR BIOLOGY | TUMOR-SUPPRESSOR GENES | apoptosis | VALPROIC ACID | cell cycle arrest | anti-angiogenic effect | CHEMISTRY, MULTIDISCIPLINARY | drug combinations | CELL LUNG-CANCER | EPITHELIAL-MESENCHYMAL TRANSITION | PHASE-II TRIAL | LONG NONCODING RNA | histone deacetylases | cancer | histone deacetylase inhibitors | Immunomodulation - drug effects | Apoptosis - drug effects | Humans | Angiogenesis Inhibitors - pharmacology | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antineoplastic Agents - therapeutic use | Clinical Trials as Topic | Autophagy - drug effects | Acetylation - drug effects | Animals | Signal Transduction - drug effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Cell Cycle Checkpoints - drug effects | Angiogenesis Inhibitors - therapeutic use | Histone Deacetylase Inhibitors - pharmacology | Antineoplastic Agents - pharmacology | Epigenesis, Genetic - drug effects | Histone Deacetylase Inhibitors - therapeutic use | Gene Expression Regulation, Neoplastic - drug effects | Drug Evaluation, Preclinical
Journal Article
Drug design, development and therapy, ISSN 1177-8881, 2015, Volume 9, pp. 4479 - 4499
.... There are several pharmacological approaches to block TGF-beta signaling, such as monoclonal antibodies, vaccines, antisense oligonucleotides, and small molecule inhibitors. Galunisertib... 
LY2157299 | Clinical trials | TGF-β | TGF-βRI kinase inhibitor | ALK5 | Galunisertib | Cancer | CHEMISTRY, MEDICINAL | RECEPTOR-TYPE-II | MESENCHYMAL TRANSITION | BREAST-CANCER | TGF-beta | HEPATOCELLULAR-CARCINOMA | TGF-beta RI kinase inhibitor | PLASMA-LEVELS | THERAPEUTIC TARGET | REGULATORY T-CELLS | PHARMACOLOGY & PHARMACY | cancer | clinical trials | TUMOR-GROWTH | galunisertib | I KINASE INHIBITOR | Phosphorylation | Pyrazoles - therapeutic use | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | Quinolines - administration & dosage | Quinolines - pharmacokinetics | Protein Kinase Inhibitors - chemistry | Pyrazoles - chemistry | Antineoplastic Agents - adverse effects | Protein-Serine-Threonine Kinases - antagonists & inhibitors | Antineoplastic Agents - pharmacokinetics | Molecular Structure | Heart Diseases - chemically induced | Pyrazoles - pharmacokinetics | Protein-Serine-Threonine Kinases - metabolism | Pyrazoles - adverse effects | Protein Kinase Inhibitors - pharmacokinetics | Drug Administration Schedule | Administration, Oral | Quinolines - chemistry | Smad2 Protein - metabolism | Neoplasms - enzymology | Treatment Outcome | Antineoplastic Agents - chemistry | Drug Discovery | Neoplasms - drug therapy | Xenograft Model Antitumor Assays | Protein Kinase Inhibitors - administration & dosage | Pyrazoles - administration & dosage | Receptors, Transforming Growth Factor beta - antagonists & inhibitors | Receptors, Transforming Growth Factor beta - metabolism | Signal Transduction - drug effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Quinolines - therapeutic use | Neoplasms - pathology | Quinolines - adverse effects | Antimitotic agents | Cellular signal transduction | Transforming growth factors | Antineoplastic agents | Health aspects | Testing | Animal models | Transcription factors | Laboratories | Toxicity | Transforming growth factor-b | Oligonucleotides | Glioblastoma | Hepatocellular carcinoma | Metastasis | Vaccines | Kinases | Drug resistance | Dosage | Cancer therapies | Anticancer properties | Metastases | Proteins | Angiogenesis | Signal transduction | Pancreatic carcinoma | Smad2 protein | Fibroblasts | Physiology | Tumorigenesis | Colon | Growth factors | Cytokines | Melanoma | Antisense oligonucleotides | Immunosurveillance | Pharmacology | Breast cancer | Lung carcinoma | Patients | Biological activity | Signaling | Inhibitors | Pancreatic cancer | Monoclonal antibodies | Ligands | Antitumor activity | Prostate cancer | Tumors
Journal Article
JAMA : the journal of the American Medical Association, ISSN 0098-7484, 06/2017, Volume 317, Issue 23, pp. 2392 - 2401
IMPORTANCE: Combining biologic monoclonal antibodies with chemotherapeutic cytotoxic drugs provides clinical benefit to patients with advanced or metastatic... 
MEDICINE, GENERAL & INTERNAL | LEUCOVORIN | FIRE-3 | THERAPY | FOLFIRI PLUS CETUXIMAB | PHASE-II | IRINOTECAN | OXALIPLATIN | FLUOROURACIL | TUMORS | PROGRESSION | Leucovorin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Bevacizumab - therapeutic use | United States | Bevacizumab - adverse effects | Colorectal Neoplasms - genetics | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antineoplastic Agents - therapeutic use | Cetuximab - therapeutic use | Cetuximab - adverse effects | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Antineoplastic Agents - adverse effects | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Angiogenesis Inhibitors - therapeutic use | Adult | Camptothecin - administration & dosage | Female | Angiogenesis Inhibitors - adverse effects | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Camptothecin - adverse effects | Kaplan-Meier Estimate | Treatment Outcome | Canada | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Colorectal Neoplasms - secondary | Aged | Genes, ras | Organoplatinum Compounds - adverse effects | Chemotherapy | Usage | Care and treatment | Research | Colorectal cancer | Cancer | Drugs | Medical research | Colorectal carcinoma | Clinical trials | Cytotoxicity | Patients | Survival | K-Ras protein | Bevacizumab | Metastases | Survival analysis | Irinotecan | Randomization | Oxaliplatin | Monoclonal antibodies | Tumors
Journal Article
Thyroid (New York, N.Y.), ISSN 1557-9077, 2014, Volume 24, Issue 5, pp. 918 - 922
...: Here, we describe three patients treated with antiangiogenic tyrosine kinase inhibitors at two academic institutions who developed aerodigestive fistula... 
Case Studies, and Patients with Remarkable Features or Rare Disorders | PHASE-II TRIAL | TRACHEOESOPHAGEAL FISTULA | BEVACIZUMAB | ENDOCRINOLOGY & METABOLISM | SORAFENIB | CARCINOMA | RADIATION-THERAPY | Anilides - therapeutic use | Postoperative Complications - etiology | Drugs, Investigational - adverse effects | Esophageal Fistula - physiopathology | Anilides - adverse effects | Humans | Middle Aged | Drugs, Investigational - therapeutic use | Esophageal Fistula - epidemiology | Male | Protein Kinase Inhibitors - adverse effects | Respiratory Tract Fistula - etiology | Respiratory Tract Fistula - chemically induced | Pyridines - adverse effects | Phenylurea Compounds - adverse effects | Fatal Outcome | Angiogenesis Inhibitors - therapeutic use | Pyrroles - adverse effects | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Pyrroles - therapeutic use | Angiogenesis Inhibitors - adverse effects | Postoperative Complications - chemically induced | Pyridines - therapeutic use | Texas - epidemiology | Esophageal Fistula - etiology | Thyroid Neoplasms - surgery | Tracheoesophageal Fistula - epidemiology | Postoperative Complications - physiopathology | Esophageal Fistula - chemically induced | Risk Factors | Phenylurea Compounds - therapeutic use | Postoperative Complications - epidemiology | Thyroid Neoplasms - radiotherapy | Tracheoesophageal Fistula - chemically induced | Academic Medical Centers | Combined Modality Therapy - adverse effects | Thyroidectomy - adverse effects | Indoles - adverse effects | Thyroid Neoplasms - drug therapy | Protein Kinase Inhibitors - therapeutic use | Neck Dissection - adverse effects | Respiratory Tract Fistula - epidemiology | Indoles - therapeutic use | Tracheoesophageal Fistula - physiopathology | Quinolines - therapeutic use | Tracheoesophageal Fistula - etiology | Respiratory Tract Fistula - physiopathology | Quinolines - adverse effects | Index Medicus
Journal Article
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2014, Volume 32, Issue 8, pp. 760 - 767
Journal Article